As Novartis’ Glivec Hearing Approaches, Indian IP Panel Adds Court-Ordered Technical Member
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Swiss pharma giant Novartis is "pleased" with the appointment of a new technical member to an Indian panel hearing a high-profile challenge by Novartis regarding the rejection of patent protection for its blockbuster leukemia drug Glivec